Insights

Q&A with Portfolio Manager, Claudia Kwan In disruptive regimes, valuation matters less — sometimes not at all — because

Genex's June quarterly report shows encouraging positive operating cashflow and a strong solar revenue.

Botanix Pharmaceuticals has announced its BTX 1702 Phase 1b/2 clinical study on papulopustular rosacea has produced clinically meaningful data. 

Volpara Health Technologies (“Volpara”), which provides clinically validated software for the early detection of breast cancer, has been certified

NEXTSTELLIS was approved by the Therapeutic Goods Administration in November 2021.

De.mem treated approximately 550 million litres of water across 15 sites in Australia and Singapore.

We are pleased that Skip Capital and Stonepeak Partners recognise the value in Genex.

MedAdvisor has announced the purchase of GuildLink from the Pharmacy Guild of Australia. This will add 934 pharmacies.

Volpara is pleased to partner with such a large and well-respected organisation as RadNet.